Amycretin: research

Amycretin dosage

Typical reported dose: Weekly shot: 0.3 mg to start, raised up to 20 mg

• Oral safety study: 1 mg: 1 mg once one dose only, by mouth. Studied in a trial. Studied in: Adults 18–55, BMI 25.0–34.9, without diabetes. (source)
• Oral safety study: 3 mg: 3 mg once one dose only, by mouth. Studied in a trial. Studied in: Adults 18–55, BMI 25.0–34.9, without diabetes. (source)
• Oral safety study: 6 mg: 6 mg once one dose only, by mouth. Studied in a trial. Studied in: Adults 18–55, BMI 25.0–34.9, without diabetes. (source)
• Oral safety study: 12 mg: 12 mg once one dose only, by mouth. Studied in a trial. Studied in: Adults 18–55, BMI 25.0–34.9, without diabetes. (source)
• Oral safety study: 18 mg: 12 mg + 6 mg together once one dose only, by mouth. Studied in a trial. Studied in: Adults 18–55, BMI 25.0–34.9, without diabetes. (source)
• Oral safety study: 25 mg: 25 mg once one dose only, by mouth. Studied in a trial. Studied in: Adults 18–55, BMI 25.0–34.9, without diabetes. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

Amycretin side effects and risks

Reported side effects

• Nausea: Diabetes injections: 11–50% by dose versus 14% placebo. Tablets: 11–35% versus 3%., moderate. Discuss persistent symptoms before any increase; large meals may worsen them. (source)
• Vomiting: Diabetes injections: 3–29% versus 6% placebo. Tablets: 7–16% versus 0%., moderate. Repeated vomiting or inability to keep fluids down needs prompt assessment. (source)
• Diarrhea: Diabetes injections: 5–37% versus 6% placebo. Tablets: 6–8% versus 7%., moderate. Watch fluid intake and urine output; seek care for dehydration. (source)
• Constipation: Early 20 mg injection arm: 44% versus 20% placebo. Diabetes injections: 3–11% versus 3%., moderate. Report persistent constipation. Severe pain, swelling or inability to pass gas needs urgent care. (source)
• Altered or sensitive skin: Diabetes injections: 21% at 40 mg versus 0% placebo; 8% at 10 mg and 5% at 20 mg., moderate. Report burning, tingling or painful skin; rule out other causes. (source)
• Reflux, indigestion and burping: Oral diabetes trial: reflux 4–10% versus 3% placebo; burping 0–6% versus 0%., mild (source)
• Fatigue or weakness: Oral diabetes trial: fatigue 2–8% versus 3% placebo; weakness 2–6% versus 0%., moderate (source)
• Faster heart rate: Week 36 diabetes injections: mean rise 1.96–8.65 beats/min across doses versus −1.40 with placebo., moderate. Report sustained racing heart, palpitations or faintness. (source)
• Acute pancreatitis: Early trial: 1 mild, non serious gallstone case in 20 mg arm; last dose 2.5 mg. Oral diabetes: 1/54 (2%) at 6 mg; other oral arms/placebo 0. Injected diabetes: 0., serious. Severe lasting upper belly pain needs urgent care; normal enzyme tests did not exclude the reported case. (source)
• Severe low blood sugar: Injected diabetes trial: 1/38 (3%) at 20 mg; all other doses and placebo 0., serious. Risk may rise with insulin or sulfonylureas; confusion or unresolved symptoms need emergency care. (source)
• Kidney injury from fluid loss: One acute kidney injury caused withdrawal at oral 50 mg: 1/51 (2%)., serious. Get care for repeated vomiting, very little urine or marked dizziness. (source)
• Gallstone disease: Injected diabetes trial: 1/36 at 1.5 mg, 1/37 at 5 mg and 1/36 placebo, each reported as 3%., serious. Right upper belly pain with fever or yellow skin needs urgent assessment. (source)

Stop and get help if

• Severe lasting upper belly pain, especially into the back, with or without vomiting: Stop exposure and get urgent medical care for possible pancreatitis.
• Swollen tongue or throat, trouble breathing, widespread hives or collapse: Call emergency services now; possible severe allergic reaction.
• Repeated vomiting, inability to drink, very little urine or marked dizziness: Get urgent assessment for dehydration or kidney injury.
• Chest pain, fainting or sustained racing heart: Call emergency services for chest pain or fainting; seek urgent care for a sustained racing heart.
• Sudden vision loss or major new vision changes: Get urgent eye assessment.
• Confusion, seizure, unconsciousness or low-glucose symptoms that do not resolve: Call emergency services. Do not give food or drink to someone who cannot swallow safely.
• Severe swollen belly, vomiting and inability to pass stool or gas: Get urgent care for possible bowel obstruction.
• Right upper belly pain with fever or yellow skin: Get urgent assessment for gallbladder or bile-duct disease.

Who should avoid it

• pregnant: Pregnant people were excluded. Fetal safety is unknown; this is an investigational appetite-suppressing drug.
• breastfeeding: Breastfeeding people were excluded. Effects on milk and infants are unknown.
• tryingToConceive: People planning pregnancy were excluded. No amycretin-specific preconception washout has been established.
• under18: Human trials enrolled adults. Safety and dosing below 18 are not established.
• mtcOrMen2: Personal or family medullary thyroid cancer or MEN2 excluded in trials; GLP-1 class precaution, not an amycretin label.
• eatingDisorderHistory: Appetite suppression may worsen unsafe restriction. Early trials excluded eating disorders; no recovery protocol is established.
• pancreatitisHistory: Trials excluded prior pancreatitis. One confirmed case occurred in the oral diabetes trial.
• gastroparesis: Severe slow stomach emptying was excluded. GLP-1 class effects may worsen symptoms.
• diabeticRetinopathy: Unstable diabetic eye disease was excluded. Rapid blood sugar improvement warrants an eye-care review.
• kidneyDisease: One low-dose kidney study was reassuring. Dehydration and long-term high-dose safety still need attention.
• liverDisease: People with substantial liver test abnormalities were excluded; a liver-impairment PK trial has no results.
• gallbladderDisease: Gallstone events occurred in the diabetes trial. Weight loss and GLP-1 class effects warrant review of prior gallbladder disease.
• heartCondition: Heart rate increased in trials; recent heart attack, stroke or unstable heart disease were excluded.
• uncontrolledBloodPressure: Uncontrolled blood pressure was excluded in early trials. Review blood pressure and heart symptoms before exposure.
• surgeryPlanned: GLP-1 class delay in stomach emptying can affect anesthesia safety. Tell the procedure team; no amycretin-specific hold schedule exists.
• diabetes: Monitor glucose closely, especially with other glucose-lowering medicines. A severe low-glucose event occurred at 20 mg.
• cancerHistory: Recent cancers were excluded from early trials. Long-term cancer safety is unknown; this does not show that amycretin causes cancer.
• other: Known or suspected serious allergy to the study drug or related products was an exclusion.
• other: Calcium/PTH disorders and prior bisphosphonate or denosumab use were excluded. Calcitonin receptor activity warrants review.
• testedAthlete: Its unapproved status brings it under WADA S0, prohibited in and out of competition.

Interactions

• Insulin: GLP-1/amylin effects plus insulin may cause low blood sugar. A combination dose-adjustment protocol for amycretin is not established.
• Sulfonylureas: Additive blood sugar lowering may cause hypoglycemia; amycretin trials did not establish this combination.
• Other GLP-1 or amylin drugs: Overlapping appetite and stomach effects; no established combination protocol. Registered switch studies test sequential use, not stacking.
• Oral medicines with narrow dosing margins: Class-based concern: stomach emptying changes may alter absorption. Drug-level or INR checks may be needed; amycretin-specific effects are unknown.
• Oral birth control: A completed amycretin birth-control interaction study has no public results. Absorption effects and any extra contraception interval are unknown.
• Bisphosphonates and denosumab: The phase 2 trial excluded prior use and calcium disorders. A calcium-related interaction is a precaution, not a measured amycretin effect.
• Metformin and SGLT2 inhibitors: These were background medicines in phase 2. That trial experience does not establish safety for every patient or other drug combinations.

Product quality risks

• No published independent assay of retail amycretin products was located. Online availability does not confirm identity, dose or sterility.
• Adjacent evidence only: three tested online semaglutide samples had 7–14% purity and 29–39% more drug than labeled.
• One semaglutide sample had endotoxin at 8.95 EU/mg despite no viable microbes. These findings cannot be assigned an amycretin contamination rate.
• Amycretin has no approved retail pen; any claimed approved amycretin pen or tablet warrants verification.
• FDA warns of unapproved GLP-1 product quality and dose errors. Its named compounding warning concerns other drugs, not an amycretin-specific ruling.

How Amycretin works

It copies two hormone signals that help control hunger and blood sugar. GLP-1 helps release insulin when blood sugar rises. Amylin adds a fullness signal. Cell tests also show calcitonin receptor activity; its separate effects in people are unclear.

• GLP-1 receptor: Helps signal fullness and release insulin when blood sugar is high.
• Amylin receptors: Adds signals that reduce eating and help people feel full.
• Calcitonin receptor: Activated in cell tests; its contribution to human benefits and harms is not established.

Half-life: About 3.3–4.1 days after injections in the first trial; 88.1 hours in people with normal kidney function in the kidney study.